Literature DB >> 299981

Pulmonary function in nonsmoking subjects with alpha1 antitrypsin deficiency (MZ phenotype).

A F Gelb, E Klein, J Lieberman.   

Abstract

We measured pulmonary functions in 10 nonsmoking asymptomatic subjects, ages 40.5 years +/- 9.2 years, with alpha1 antitrypsin heterozygous deficiency (phenotype MZ). The subjects were longstanding residents of the greater Los Angeles area. The range of physiologic studies and per cent of normal predicted values were forced vital capacity (FVC), 2.8 to 7.0 liters (86 to 124 per cent predicted); ratio of the forced expiratory volume in 1 second to the FVC, 70 to 86 per cent (86 to 104 per cent predicted); the ratio of the residual volume to total lung capacity, 28 to 44 per cent (94 to 119 per cent predicted); total lung capacity, 4.8 to 9.8 liters (80 to 119 per cent predicted); flow at 50 per cent FVC, 3.1 to 7.8 liters per second (69 to 140 per cent); and volume of isoflow, 7.3 to 26 per cent of forced vital capacity (38 to 137 per cent predicted). In eight patients studied, static deflation pressure volume curves were normal, and at respiratory rate of 60 breaths/min the ratio of dynamic compliance to static compliance did not fall below 84 per cent. We have found that these nonsmoking heterozygotes with alpha1 antitrypsin deficiency have normal pulmonary functions (within 1.67 SD of predicted mean).

Entities:  

Mesh:

Year:  1977        PMID: 299981     DOI: 10.1016/0002-9343(77)90354-0

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  6 in total

Review 1.  alpha-1-Antitrypsin and the pathogenesis of emphysema.

Authors:  R A Stockley
Journal:  Lung       Date:  1987       Impact factor: 2.584

2.  Smoking and intermediate alpha1-antitrypsin deficiency and lung function in middle-aged men.

Authors:  C Larsson; S Eriksson; H Dirksen
Journal:  Br Med J       Date:  1977-10-08

3.  Assessment of alpha-1-antitrypsin deficiency heterozygosity as a risk factor in the etiology of emphysema. Physiological comparison of adult normal and heterozygous protease inhibitor phenotype subjects from a random population.

Authors:  D J McDonagh; S P Nathan; R J Knudson; M D Lebowitz
Journal:  J Clin Invest       Date:  1979-02       Impact factor: 14.808

Review 4.  Chronic obstructive pulmonary disease in alpha1-antitrypsin PI MZ heterozygotes: a meta-analysis.

Authors:  C P Hersh; M Dahl; N P Ly; C S Berkey; B G Nordestgaard; E K Silverman
Journal:  Thorax       Date:  2004-10       Impact factor: 9.139

5.  Danazol-induced augmentation of serum alpha 1-antitrypsin levels in individuals with marked deficiency of this antiprotease.

Authors:  J E Gadek; J D Fulmer; J A Gelfand; M M Frank; T L Petty; R G Crystal
Journal:  J Clin Invest       Date:  1980-07       Impact factor: 14.808

6.  Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects.

Authors:  J E Gadek; H G Klein; P V Holland; R G Crystal
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.